Efficacy of Satralizumab (SA237) As Add-on Therapy in Pre-Specified Additional Analyses of Sakurasky, a Double-Blind Placebo-Controlled Phase 3 Study in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)
Title:
Efficacy of Satralizumab (SA237) As Add-on Therapy in Pre-Specified Additional Analyses of Sakurasky, a Double-Blind Placebo-Controlled Phase 3 Study in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)
Author:
Yamamura, Takashi Kleiter, Ingo Fujihara, Kazuo Palace, Jacqueline Greenberg, Benjamin Zakrzewska-Pniewska, Beata Patti, Francesco Saiz, Albert Haramura, Masayuki Terada, Yusuke